All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 8 read as filed from the record and 1 is an SI estimate, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
1 warning event since 2017; the latest 2025-11-28.
From the record
AbCellera Biologics Inc.'s filings since 2017 show 1 warning event: an auditor change (8-K item 4.01, the latest 2025-11-28) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
+36.5% a year over 7 filed years; profitable in 3 of 7.
From the record
AbCellera Biologics Inc.'s 7 filed years say what it did: revenue went from $12 million in fiscal 2019 to $75 million in fiscal 2025, up 36.5% a year; it rose in 4 of 6 years; the deepest fall was 94% from fiscal 2022 to fiscal 2024; net income was positive in 3 of 7 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 9.4/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: AbCellera Biologics Inc.'s shareholder treatment is put at 9.4 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the top 6% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
ROE -15%: lost 15¢ per shareholder dollar. Leverage 29%: owes 29¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, AbCellera Biologics Inc. lost about 15 cents for every dollar of shareholders' money. Leverage: it owed about 29 cents per dollar of assets, and net share issuance: its share count grew 1.5% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
bottom 40% of 315 in its family; net margin -194.9%.
From the record
AbCellera Biologics Inc.'s standing among 315 graded names in its industry family: revenue of $75 million in fiscal 2025 ranks in the top 38% by size; a net margin of -194.9% ranks in the bottom 47%; revenue growth of -46.3% a year over the last 3 filed years ranks in the bottom 11% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
top 44% of 315 in its family for leadership; chief executive since 2020.
From the record
AbCellera Biologics Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Hansen, Carl L. G. (Chief Executive Officer, as filed), filing under that title since 2020-12-11, 5.9 years (top 41% of its family); the 9 officers and directors filing in the last fifteen months have been on the record a median of 5.9 years (top 44%); 4 officer or director changes were reported on Form 8-K since 2023-11-13, against the 9 people in charge now (top 47%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
bottom 43% of 273 in its family for room to expand.
From the record
AbCellera Biologics Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $129 million against no long-term debt tagged leaves 9.5% of its assets as net cash, bottom 25% of its family; cash from operations less capital spending is -231.7% of revenue (bottom 42%); research spending of 248.7% of revenue (top 39%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
top 45% of 306 in its family for growth drivers.
From the record
AbCellera Biologics Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew -46.3% a year over the last three filed years against 36.5% over all 7, slowing (bottom 6% of its family); the newest year grew 160.7% (top 12%); research spending grew 20.1% a year (top 23%); capital spending grew -15.4% a year (top 50%) (its annual reports). AbCellera Biologics Inc. reported 3 product lines in fiscal 2025: License at $47 million (63%), Research Fees at $27 million (36%), Milestone Payments at $1 million (1%); 2 of 3 grew against the year before (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
top 43% of 233 in its family for expectations against reality.
From the record
AbCellera Biologics Inc.'s newest year against its own record: revenue of $75 million in fiscal 2025 came in 968.1% above the $7 million its prior three years' pace pointed to (top 7% of its family); net income of $146 million against a prior three-year average of $50 million (bottom 9%); a net margin of a loss larger than its revenue against losses larger than its revenue before (top 30%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made